Edition:
United Kingdom

Neurotrope Inc (NTRP.OQ)

NTRP.OQ on NASDAQ Stock Exchange Capital Market

8.50USD
16 Feb 2018
Change (% chg)

$0.08 (+0.95%)
Prev Close
$8.42
Open
$8.36
Day's High
$8.76
Day's Low
$8.31
Volume
4,036
Avg. Vol
8,673
52-wk High
$21.31
52-wk Low
$3.41

Chart for

About

Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the... (more)
No analyst recommendations are available for .

Overall

Beta: 3.38
Market Cap(Mil.): $40.11
Shares Outstanding(Mil.): 7.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.63 16.64
EPS (TTM): -- -- --
ROI: -- 11.84 10.66
ROE: -- 13.87 14.30

BRIEF-Neurotrope's Bryostatin Improves Cognition In Patients

* NEUROTROPE'S BRYOSTATIN IMPROVES COGNITION IN PATIENTS WITH ADVANCED ALZHEIMER'S DISEASE BASED ON FURTHER ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA Source text for Eikon: Further company coverage:

05 Jan 2018

BRIEF-Neurotrope Appoints Charles S. Ryan As CEO

* NEUROTROPE APPOINTS CHARLES S. RYAN AS CHIEF EXECUTIVE OFFICER

18 Dec 2017

Earnings vs. Estimates